Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Carrier Do You Suggest? Vote - 2Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- 3Inconceivable Spots To Stargaze All over The Planet
- 4Extravagance SUVs for Seniors: Solace, Innovation, and Security
- 5As nations push for more ambition at climate talks, chairman says they may get it
- 23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- Vote in favor of Your Number one Cake Type
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- Lula’s former human rights minister formally accused of sexual misconduct
- Instructions to Pick the Right Senior Protection Plan.
- Will Comet C/2025 R3 (PanSTARRS) be the 'great comet' of 2026?
- Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
